Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nathan Chung

Surgery Apple Valley, CA Medical Doctor

NPI 1144249152 CMS profile 324372

19341 Bear Valley Road, Suite 205, Apple Valley, CA 92308

Open in the dashboard

General payments

$9,371

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nathan Chung of Apple Valley, CA is reported in the CMS Open Payments database as having received $9,371 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,214 17
2024 General $924 18
2023 General $1,734 39
2022 General $1,844 27
2021 General $838 16
2020 General $476 7
2019 General $2,340 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nathan Chung
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Nathan Chung were reported at $1,214. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Nathan Chung Surgery median Middle half National median
2019 $2,340 $253 $82–$1,521 $163
2020 $476 $131 $40–$706 $114
2021 $838 $168 $50–$904 $132
2022 $1,844 $224 $76–$1,218 $149
2023 $1,734 $253 $82–$1,255 $160
2024 $924 $279 $90–$1,381 $164
2025 $1,214 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $5,515 105 payments
  2. Smith+Nephew, Inc. $1,034 13 payments
  3. KCI USA, Inc $758 2 payments
  4. W. L. Gore & Associates, Inc. $611 5 payments
  5. ConvaTec Inc. $390 4 payments
  6. Intuitive Surgical, Inc. $239 2 payments
  7. Musculoskeletal Transplant Foundation Inc. $193 2 payments
  8. Osiris Therapeutics Inc. $164 2 payments
  9. Merck Sharp & Dohme Corporation $120 7 payments
  10. AngioDynamics, Inc. $105 1 payment
  11. Other $243 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,091 148 payments
  2. Consulting Fee $650 1 payment
  3. Travel and Lodging $416 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $213 2 payments
Products named General payments · program years 2019–2025
  1. Puraply $2,759 58 payments
  2. SNAP $758 2 payments
  3. BIO-A Tissue Reinforcement $560 3 payments
  4. Affinity $551 7 payments
  5. Stravix $285 3 payments
  6. CYGNUS MATRIX $279 3 payments
  7. Apligraf $276 6 payments
  8. GRAFIX PL Other Advanced Wound Management $272 2 payments
  9. GRAFIX PL Other Advanced Wound Management $271 2 payments
  10. Puraply Antimicrobial $258 6 payments
  11. Other $4,731 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

162

Median for General Surgery: 59

Drug cost

$7,163

Median for General Surgery: $393

Branded share of claims

34.6%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 11 $5,424
Gentamicin Sulfate Generic 18 $792
Doxycycline Hyclate Generic 37 $269
Cephalexin Generic 33 $218
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 21 $180
Ssd Silver Sulfadiazine Brand 12 $135
Mupirocin Generic 18 $108
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 12 $38

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$192,352

Medicare's payments for the services billed

Medicare patients

415

Average age 79

Services billed

3,277

211 women, 204 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 40%
Chronic kidney disease 39%
Diabetes 37%
Atrial fibrillation 36%
Heart failure 33%
Cancer 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record